Jeffrey Jones, MD, discusses small molecule inhibitors of B-cell receptor signaling in chronic lymphocytic leukemia (CLL).
Jeffrey Jones, MD, assistant professor of Internal Medicine, Ohio State University Comprehensive Cancer Center, discusses small molecule inhibitors of B-cell receptor signaling in chronic lymphocytic leukemia (CLL). Jones says both idelalisib and ibrutinib have been highly effective in the majority of relapsed/refractory CLL.
Jones says that while idelalisib and ibrutinib have been effective overall, there is a small group of patients who cannot receieve the treatment. He says that a different option for patients who cannot undergo those treatments are BCL-2 inhibitors like venetoclax. He adds that in a recent study, venetoclax has proven to be effective in the patient population with CLL who cannot receieve idelalisib and ibrutinib due to toxiticies or high-risk genetic features.
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
Fitting Loncastuximab Into the Current Landscape of R/R DLBCL
March 21st 2024During a Case-Based Roundtable® event, Emily Ayers, MD, discussed the current landscape for the treatment of patients with diffuse large B-cell lymphoma, the need for better risk stratification data, and what led to the approval of loncastuximab tesirine in the first article of a 2-part series.
Read More
Lachowiez Considers the Use of Tagraxofusp in BPDCN as Bridge to SCT With Peers
March 21st 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Curtis Lachowiez, MD, discussed targeted therapy for blastic plasmacytoid dendritic cell neoplasm and its role in patients who could receive allogeneic stem cell transplant.
Read More